USP Top Quality Apis Lapatinib 231277-92-2 for Breast Cancer Treatment
|10-99 100-499 500-999 1,000+|
|FOB Unit Price:||US $11 US $10 US $9 US $8|
|Purchase Qty. (gram)||FOB Unit Price|
|Port:||Hong Kong, Hong Kong|
|Production Capacity:||Mass Stock|
|Payment Terms:||T/T, Western Union, Money Gram, Bitcoin|
- Model NO.: 231277-92-2
- Customized: Non-Customized
- Suitable for: Adult
- Purity: >99%
- Mf: C29h26clfn4o4s
- MOQ: 10 Grams
- Transport Package: Disguised Package or as Required
- Origin: China
- Powder: Yes
- Certification: GMP, HSE, ISO 9001, USP, BP
- State: Solid
- Appearance: White Powder
- MW: 581.0575432
- Trademark: LSW
- Specification: SGS GMP
- HS Code: 3002200000
1. Quick Details:
|Deliver methods:||By express(door to door)|
|Deliver time:||About 5 days|
|Product Categories:||Molecular Targeted Antineoplastic;anti-neoplastic;Pharmaceutical intermediate;APIs;API;Lapatinib;Anti-cancer&immunity;Inhibitors|
2. What is Lapatinib:
Lapatinib (also known as Tyverb) is a targeted therapy and is one of a group of cancer drugs called tyrosine kinase inhibitors.
Lapatinib , used in the form of lapatinib ditosylate (USAN) (trade names Tykerb and Tyverb) is an orally active drug for breast cancer and other solid tumours.It is a dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways.It is used in combination therapy for HER2-positive breast cancer. It is used for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 (ErbB2).
Lapatinib is used together with another medication to treat a certain type of breast cancer (HER2-positive) that has not responded to the standard treatment. Lapatinib may also be used together with another medication to treat HER2-positive breast cancer in women after menopause. It works by slowing or stopping the growth of cancer cells.
Lapatinib is used as a treatment for women's breast cancer in treatment-naïve, ER+/EGFR+/HER2+ breast cancer patients and in patients who have HER2-positive advanced breast cancer that has progressed after previous treatment with other chemotherapeutic agents, such as anthracycline, taxane-derived drugs.
A 2006 GSK-supported randomized clinical trial on female breast cancer previously being treated with those agents (anthracycline, a taxane and trastuzumab) demonstrated that administrating lapatinib in combination with capecitabine delayed the time of further cancer growth compared to regimens that use capecitabine alone. The study also reported that risk of disease progression was reduced by 51%, and that the combination therapy was not associated with increases in toxic side effects.The outcome of this study resulted in a somewhat complex and rather specific initialindication for lapatinib-use only in combination with capecitabine for HER2-positive breast cancer in women whose cancer have progressed following previous chemotherapy with anthracycline, taxanes and trastuzumab.
4. How does lapatinib work?
Some breast cancers have higher than normal levels of proteins (also known as receptors) called human epidermal growth factor 2 (HER2) and epidermal growth factor (HER1) also known as epidermal growth factor receptor (EGFR), which stimulate cancer cells to divide and grow.
Lapatinib is known as a dual kinase inhibitor because it targets both HER2 and HER1 receptors. It works inside the cancer cells blocking the signals that make the cells grow.
5. Who might be offered lapatinib?
Lapatinib may not be widely available and there are national variations on its availability. Your specialist will be able to tell you if it's likely you'll be able to receive it. Find out more about the availability of cancer drugs.
Only people whose cancer has high levels (over expression) of HER2 may benefit from having lapatinib. This is known as HER2 positive breast cancer and is found in around 20% of people with breast cancer.
Lapatinib may be used as a treatment for secondary breast cancer (breast cancer that has spread to other parts of the body). It's usually given alongside other cancer drugs.
People who have already had treatments for HER2 positive secondary breast cancer, such as chemotherapy or trastuzumab may be suitable for lapatinib, although this may be within a clinical trial alongside other drugs. When it is given for secondary breast cancer lapatinib is usually taken for as long as it is keeping the cancer under control.
Lapatinib is not currently given for primary breast cancer. However clinical trials are looking at whether it may be useful.
6. How to Take Lapatinib (Dosage):
All possible dosages and forms may not be included here. Your dose, form, and how often you take it will depend on:
the condition being treated
how severe your condition is
other medical conditions you have
how you react to the first dose
7. Our Adwantage:
High quality with competitive price:
1) Standard: Enterprise Standard
2) All Purity:>=99%
3) We are manufacturer and can provide high quality products with factory price.
Fast and safe delivery:
1) Parcel can be sent out in 24 hours after payment. Tracking number available
2) Secure and discreet shipment. Various transportation methods for your choice.
3) Customs pass rate: >=99%
4) We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.
We have clients throughout the world:
1) Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2) Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3) High quality, competitive price, fast delivery, first-class service gain the trust and praise from the customers.
Everybody is talking the similar words, what I want to say is: Just give me a chance, Just have a try on me, maybe you will get a surprise from me!